San Francisco · Pre-Seed–Series A · 20 people tracked
Also known as AWESOME ENABLERS, L.L.C. · BIOINNOVATION MANAGEMENT LLC · MBC FII MANAGEMENT, LLC · MISSION BIOCAPITAL MANAGEMENT COMPANY LLC
Investment thesis
Mission BioCapital invests early-stage capital in life science startups, pairing funding with a platform that includes shared lab space to accelerate the journey from scientific discovery to medical breakthrough. The firm emphasizes collaboration, mentorship, innovation in deal structuring, and respect for founders. Its team of scientists, investors, founders, and serial entrepreneurs has a long history of launching and building early-stage life science companies. Investing out of its fifth fund, the firm aims to be a partner from a founder's first experiment through to the clinic, helping deliver scientific solutions faster and more efficiently to individuals and communities in need.
Source: firm website, verified Aug 25, 2026.
Team · 20 people
from the firm's website
What they invest in
from 55 of 64 portfolio companiesBiotech ×46Medical Devices ×30Healthtech ×21Deep Tech ×15AI & Machine Learning ×7Consumer ×4Longevity ×4Climate Tech ×3
HQs:United States×45Azerbaijan×1
Who they back
founder profiles across 37 portfolio companiesFounding team size:solo founder×172 founders×93 founders×64+ founders×5
Where their founders studiedfrom 17 founders with education data
University of California, Berkeley ×5Harvard University ×3The Johns Hopkins University ×2The University of Texas at Austin ×2Yale School of Management ×2
Where their founders worked beforefrom 16 founders with career history
Harvard Medical School ×5Stanford University ×2
Accelerator rootsportfolio companies that came through a program
Investments · 64 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 42024 · 22023 · 12022 · 12021 · 22019 · 12015 · 22014 · 216 dated
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.
AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US
Arnon Rosenthal(Ph.D.)Tillman Gerngross(Director)Arnon Rosenthal PhD(Founder)in
BoardCarl Gordon(Director)Terry McGuire(Director)in
Co-investorsForesite CapitalMission Bay CapitalMRL Ventures FundSV Health InvestorsPolaris Partners
Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform.
BiotechMedical DevicesBerkeley, US
Jennifer Doudna(Co-founder)Rachel Haurwitz(President and Chief Executive Officer, Co-founder)Martin Jinek(Co-founder)Andrew May(Executive Officer)
BoardJenny Rooke(Director)Robert Weisskoff(Director)in
Co-investorsAliment CapitalAvego BioScience CapitalF-Prime CapitalIA Seed VenturesMission Bay CapitalPontifax AgTech+2 more
Arase Therapeutics develops first-in-class oncology therapeutics that target ADP-ribose Hydrolases, novel proteins in cancer stress pathways.
BiotechMedical Devices
Paul Chang(President, CEO / CSO and Lead Founder)W. Lee Kraus(Scientific Founder)Michael Taylor(Executive Chairman)in
Co-investorsPortal Innovations
March Bioscience is a cell therapy company assembling leading scientists and drug developers to advance cell therapy treatments.
BiotechMedical DevicesHouston, US
Sarah Hein(CEO, Co-Founder)inMaksim Mamonkin(Co-Founder, Chair Scientific Advisory Board)Malcolm Brenner(Co-founder)
BoardThomas Luby(Director)inPeter Olagunju(Director)inJoseph Petrosino(Director)
Co-investors4BIO CapitalCancer FundFitz Gate VenturesModi VenturesPortal InnovationsTMC Venture Fund+1 more
Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer.
BiotechHealthtechMedical DevicesSan Carlos, US
Pamela Munster(Founder, Chief Scientific Advisor and Director)Cam Gallagher(Executive Officer, Director)inJohn Maroney(Executive Officer, Director)
BoardZachary Collins(Executive Officer)inAnnie Mitsak(Director)in
Board seatDouglas CrawfordSteve Tregay· per SEC Form D
Co-investorsCure VenturesMission Bay Capital
A venture studio embedded within Alloy Therapeutics that partners with academics, entrepreneurs, pharma companies, and VCs to create and develop early-stage drug discovery companies.
BiotechDeep TechWaltham, US
Errik B. Anderson(Executive Officer, Director)inPiotr Bobrowicz(Executive Officer, Director)Jay Rosanelli(Executive Officer)
BoardAnthony Sun(Director)Alaa Halawa(Director)Ulrik Nielsen(Director)in
Board seatUlrik B. Nielsen· per SEC Form D · $40M raise · filed Apr 2026
Co-investors82VS8VCJIC Venture Growth InvestmentsMC Healthcare Ventures
Cambridge, US
Board seatSteve Tregay· per SEC Form D · $170.2M raise · filed Jul 2018
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)Brian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Board seatCassidy Blundell· per SEC Form D
Co-investorsLongwood FundNovartis Venture FundOno Venture Investment, Inc.Pfizer Venture InvestmentsShangBay Capital LLCSofinnova Partners+2 more
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.
BiotechDeep TechMedical DevicesWatertown, US
Dmitrij Hristodorov(Director)Christopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)
BoardAleks Radovic-Moreno(Director)inDan Janney(Director)
Board seatCassidy Blundell· per SEC Form D
Co-investorsAlta PartnersLongwood FundDolby Family VenturesForbionService Provider Capital
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)Roet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)Jason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)
Board seatJohannes Fruehauf· per SEC Form D
Co-investorsDroia VenturesMC Healthcare VenturesMitsui Global InvestmentSanofi VenturesSV Health InvestorsAmgen Ventures+6 more
Telo Therapeutics is a biotechnology company developing orally bioavailable next-generation small-molecule inhibitors of nuclear transport as cancer treatments.
BiotechHealthtechMedical DevicesSan Francisco, US
Rob Bell(Founder)inRobert Bell(Executive Officer, Director)inJoseph Costello(Director)Michael D. Taylor(Director)in
BoardRobert G. Blazej(Director)in
Board seatRobert BlazejMichael Taylor· per SEC Form D · $10.2M raise · filed Jun 2022
BiotechCambridge, US
Livio Valenti(Executive Officer)Kathryn Kosuda(Executive Officer, Director)Michael Schrader(Executive Officer, Director)Matthew Dirckx(Executive Officer)Lynda Tussey(Executive Officer)John Spiridigliozzi(Executive Officer)
Board seatJohannes Fruehauf· per SEC Form D
Co-investorsGlobal Health Investment CorporationRA Capital
AI Proteins designs engineered miniproteins for drug discovery and development in the biopharmaceutical industry.
AI & Machine LearningBiotechDeep TechAndover, US
Chris Bahl(Executive Officer, Director)inDominique Verhelle(Director)Bill McKee(Director)Julia Novina(Executive Officer)Marc A. Cohen(Executive Officer, Director)inGeoff Meyerson(Director)
Co-investorsTachyon VenturesCobro Ventures
Nobell Foods produces plant-based dairy cheese made from soybean plants engineered to grow casein protein, working with Midwest farmers.
BiotechClimate TechConsumerFoodTechSan Francisco, US
Magi Richani(Founder/CEO)in
BoardChris Rivest(Director)Vijay Pande(Director)inKyle Vogt(Director)
Co-investorsAndreessen HorowitzDCVC (Data Collective)Unovis Asset ManagementY CombinatorAgFunder
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)Josh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Co-investorsDroia VenturesMRL Ventures FundNextech InvestInkefRA Capital
Avvio Medical develops Microbubble SonoLithotripsy, a minimally invasive outpatient procedure that uses low-intensity ultrasound to break down ureteral stones without requiring general anesthesia or stents.
Deep TechHealthtechMedical DevicesSan Francisco, US
Co-investorsBaruch Future VenturesBerkeley CatalystMission Bay Capital
Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.
ConsumerGamingBaku, AZ
Co-investorsAtlas VenturePfizer Venture InvestmentsPfizer Ventures
Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.
BiotechHealthtechMedical DevicesSan Francisco, US
Ivana Djuretic(Founder)inAndy Yeung(Founder)in
Co-investorsEmles Venture PartnersGoAhead VenturesMission Bay CapitalRA CapitalY CombinatorJanus Henderson Investors+2 more
BiotechRedwood City, US
William Robinson(Director)Lawrence Steinman(Director)Tito Serafini(Executive Officer, Director)
BoardBrian Atwood(Director)Franklin Berger(Director)
Co-investorsAisling CapitalEcoR1 CapitalMission Bay Capital
Co-investorsMission Bay Capital
Bolt Threads was a manufacturer of biomaterials for personal care formulations.
BiotechNew MaterialsFoxboro, US
Ethan Mirsky(Executive Officer)David Breslauer(Executive Officer, Director)Daniel Widmaier(Executive Officer, Director)
BoardJerry Fiddler(Director)Steven Vassallo(Director)inJim Kim(Director)
Co-investorsMission Bay Capital8VCBaillie GiffordEast West Capital LimitedFidelity InvestmentsFoundation Capital+2 more
Co-investorsMission Bay CapitalLongwood Fund
Cavalry Biosciences is a biopharmaceutical company focused on developing medicines that leverage the body's inherent regenerative and repair mechanisms, particularly in areas of age-related disease and tissue regeneration.
BiotechDeep TechLongevityMedical Devices
Jan van Deursen, PhD(Co-founder, Advisor)inNathaniel (Ned) David, PhD(Co-founder, Chairman)in
Co-investorsVenrockEshelman Ventures, LLC
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)Matthew Jacobson(Director)David J. Earp(President & CEO)Paul Park(Executive Officer)
BoardThilo Schroeder(Director)in
Co-investorsBerkeley CatalystLifeforce CapitalMission Bay CapitalNextech InvestPandect BioventuresThe Column Group+1 more
Cambridge, US
ENEJ KUSCER, PH.D.(Executive Officer)PETER VAN VLASSELAER, PH.D.(Director)HENRIJETTE RICHTER, PH.D.(Director)BERNARDUS MACHIELSE(Director)LUCAS DE BREED(Director)DAVID DE GRAAF, PH.D.(Executive Officer, Director)
Co-investorsSofinnova Partners
CookieYes is a cookie consent management platform that helps businesses comply with global data privacy regulations including GDPR, CPRA, and LGPD.
AdTechEnterprise SoftwareSaaSUnited Kingdom, India
Anvar T K(Founder)in
Co-investorsBrighteye VenturesChemistryE4E AfricaEight Roads VenturesEntrepreneur FirstFf Venture Capital+16 more
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Executive Officer, Director)
BoardIvan Trifunovich(Director)John Wesley(Director)
Co-investors8VCAisling CapitalMission Bay CapitalOlive Tree CapitalSR One Capital ManagementTaiho Ventures, LLC+1 more
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.
BiotechSolana Beach, US
Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)
BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)
Co-investorsAstellas Venture Management LLCMission Bay CapitalOUP (Osage University Partners)Pfizer Venture InvestmentsUS Venture PartnersSofinnova Ventures
Eikonizo develops small molecule therapeutics targeting neurodegenerative and cardiorenal diseases.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBeverly, US
Janice Kranz, PhD(Founder)inWilliam Shaw(Executive Officer, Director)Stacie Weninger(Director)Janice Kranz(Executive Officer, Director)
BoardKevin Kinsella(Director)
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical DevicesSan Mateo, US
Ann Lee-Karlon(Executive Officer, Director)Mitchell Mutz(Executive Officer, Director)James Wells(Director)
BoardSamuel Bjork(Director)Alexandra Cantley(Director)Seiji Miyahara(Director)
Co-investorsAvego BioScience CapitalGV (Google Ventures)Novartis Venture FundRoche Venture FundSamsara BioCapitalTaiho Ventures, LLC+3 more
Epiodyne develops small-molecule opioids designed to optimize therapeutic outcomes, with initial focus on safer pain relief and improved opioid use disorder treatment with reduced addiction and respiratory depression risk.
BiotechHealthtechMedical DevicesSan Francisco, US
Brian Shoichet(Director)Douglas Crawford, Ph.D.(CEO)Don Gehlert, Ph.D.(Head of Biology)
BoardDouglas Crawford(Executive Officer, Director)in
Co-investorsMenlo VenturesMission Bay CapitalKleiner Perkins
BiotechDeep TechHardware
Co-investorsClaremont Creek VenturesMission Bay CapitalSignet Healthcare Partners
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.
Biotech
Steven Axon(Chief Executive Officer)Hicham Alaoui(Chief Scientific Officer)Rose Marino(Chief Medical Officer)Peter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)
Co-investorsAdvent Life SciencesMission Bay CapitalRemiges Ventures, Inc.RiverVest Venture PartnersSanderling VenturesSanofi Ventures
Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases.
BiotechHealthtechMedical Devices
Co-investorsBioMedPartnersLightspeed Venture PartnersPfizer Venture InvestmentsPfizer Venturesredalpine
Invenio develops rapid on-site tissue imaging systems combined with AI to improve cancer patient care.
AI & Machine LearningBiotechDeep TechMedical DevicesSanta Clara, US
Jay Trautman(President & CEO, Co-Founder)Chris Freudiger(Chief Technology Officer, Co-Founder)Christian Freudiger(Director)Xiaoliang Xie(Director)
BoardDoug Crawford(Director)in
Co-investorsBerkeley CatalystMission Bay Capital
Jupiter is a biotech company that discovers and develops new medicines across multiple therapeutic areas.
BiotechChapel Hill, US
Ned Sharpless(Co-founder & CEO)Leigh Delacy(Co-founder & Partner and COO)
Co-investorsEshelman Ventures, LLC3one4 CapitalBEENEXTHummingbird VenturesLB InvestmentPeak XV Partners+2 more
Kit provides email marketing and commerce tools for creators and independent businesses to reach audiences and monetize their work through newsletters and storefronts.
Creator EconomyMarketing TechSaaS
Nathan Barry(Founder + CEO)in
Co-investorsAUTHENTIC VENTURESBrighter CapitalExpaMission Bay CapitalWAGMI VenturesOceans Ventures+1 more
LogicInk develops wearable biochemical sensors that detect environmental and personal health signals—such as UV exposure, air quality, and microbiome changes—to provide real-time wellness feedback.
BiotechConsumerHardwareHealthtechWellness & FitnessSan Francisco, US
Carlos Olguin(Founder & CEO)inHendrik Dietz(Scientific Co-Founder)in
Co-investorsKrillion VenturesAtypical VenturesVillage GlobalBerkeley Catalyst
Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
BiotechDeep TechMedical DevicesBrisbane, US
Jennifer Doudna(Founder)inTrevor Martin(Co-founder, Chief Executive Officer)inJanice Chen(Co-founder, Chief Scientific Officer & President, Research)inLucas Harrington(Co-founder)inAshley Tehranchi(Executive Officer, Director)
BoardUrshit Parikh(Director)
Co-investors8VCBerkeley FrontierCALIFORNIA INNOVATIONDecheng CapitalForesite CapitalMayfield Fund+9 more
Myka Labs develops AI-powered sensor systems and medical devices for minimally invasive surgical repair of congenital birth defects, particularly tracheoesophageal malformations.
AI & Machine LearningDeep TechMedical DevicesSan Francisco, US
Michael Harrison(Founder and Chief Scientific Officer)Daniel Laser(CEO)Lee Swanstrom(Chief Medical Officer)
Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration.
BiotechHealthtechLongevity
Irene Griswold-Prenner(Founder & Chief Executive Officer)
Co-investorsSofinnova PartnersDementia Discovery FundMission Bay Capital
Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.
BiotechHealthtechMedical DevicesWatertown, US
MATTHEW FRANKEL(Executive Officer)PETER COUROSSI(Executive Officer)RICHARD BATYCKY(Executive Officer, Director)JAMES ELLIS(Executive Officer)MICHAEL LIPP(Executive Officer)CHRISTOPHER SILBER(Executive Officer)
Co-investorsCanaan PartnersF-Prime CapitalMonograph Capital PartnersOUP (Osage University Partners)Osage University Partners
Nuvig Therapeutics develops immune-modulating medicines for autoimmune diseases by harnessing endogenous regulatory mechanisms to resolve immune dysregulation.
BiotechHealthtechMedical Devices
Pamela Conley(Founder)in
Co-investorsB Capital GroupB4 CapitalGlobal BioAccess FundSanofi VenturesDigitalis VenturesNorwest Venture Partners
PanTher develops targeted cancer therapeutics that deliver drugs directly to tumor sites at high concentrations over extended periods, aiming to improve clinical outcomes while reducing side effects.
BiotechHealthtechMedical DevicesAustin, US
Laura Indolfi(Chief Executive Officer and Co-Founder)Elazer Edelman(Director)
BoardD Mackey(Director)Daniel Wildman(Director)Darshana Zaveri(Director)Maria Palasis(Director)
Co-investorsCatalyst Health VenturesAngel Physicians FundWalnut Venture Associates
HealthtechSan Francisco, US
Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)Leon Chen, Ph.D.(Director)Carol Gallagher(Director)Joshua Resnick, M.D.(Director)
BoardMichael Powell(Director)
Co-investorsMission Bay CapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sofinnova VenturesSofinnova Venture Partners
BiotechSouth San Francisco, US
MARTIN BABLER(Executive Officer, Director)
BoardPETER THOMPSON(Director)SRINIVAS AKKARAJU(Director)MICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)
Co-investorsAccess BiotechnologySofinnova VenturesMission Bay CapitalNew Leaf Venture PartnersOrbiMedSamsara BioCapital
Developed site-specific protein conjugation and linker technologies; acquired by Catalent Pharma Solutions in 2014.
BiotechEmeryville, US
DAVID RABUKA(Executive Officer, Director)MICHAEL BLANK(Executive Officer)KAREN M BOEZI(Executive Officer, Director)
BoardJ GORDON FOULKES(Director)EDWARD MCCRACKEN(Director)BARRY LITTLEJOHNS(Director)
Co-investorsTakeda Ventures
Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.
AI & Machine LearningBiotechDigital HealthMedford, US
Jerrold Rosenbaum(Director)inJacob Hooker(Executive Officer, Director)inPranav Tadi(Executive Officer)
BoardRyan Katz(Director)inKevin Lalande(Director)inRichard Simon(Director)
Co-investorsBonaventure Equity, LLCHatteras Venture PartnersIter InvestmentsRoute 66 VenturesService Provider CapitalSante Health Ventures
ShapeTX develops programmable RNA medicines by combining artificial intelligence with RNA technology to address genetic causes of disease.
AI & Machine LearningBiotechDeep Tech
Josef von Rickenbach, PhD(Co-Founder)in
Co-investorsNew Enterprise Associates (NEA)Decheng Capital
Deep tech company; invested from Fund I in 2015
BiotechBozeman, US
Justin DuBois(Director)George Miljanich(Executive Officer)Stan Abel(Executive Officer, Director)
BoardWill Price(Director)inLowell Sears(Director)Joseph Zakrzewski(Director)
Co-investorsNext Frontier CapitalNovo HoldingsOrbiMed
Co-investorsBioBritNext Frontier Capital
Sound Agriculture develops bio-inspired soil and crop solutions that reduce synthetic fertilizer use and improve nutrient efficiency for growers.
AgTechCleantechClimate TechImpact & Social Good
Eric Davidson, PhD(Founder)Travis Bayer, PhD(Founder)
Co-investorsFall Line Capital
Symbiome develops skin microbiome-based wellness products that restore ancestral skin health through proprietary fermentation and Amazonian botanical ingredients.
ConsumerHealthtechWellness & FitnessSan Francisco, US
Larry Weiss(Executive Officer, Director)Adam Klausner(Executive Officer)Vicki Levine(Executive Officer, Director)
BoardAdam D'Augelli(Director)in
Co-investorsBold Capital PartnersTrue Ventures
Tangible Science develops contact lens solutions designed to improve comfort and durability for wearers and to provide eye care professionals with more effective treatment options.
HealthtechMedical DevicesMenlo Park, US
Karen Havenstrite(Director)Victor McCray(Executive Officer, Director)
BoardDouglas Crawford(Director)inHanson Gifford(Director)Chip Heath(Director)Brandon Felkins(Director)
Co-investorsLightstone Ventures
Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications.
BiotechDeep TechHealthtechLongevityMedical DevicesDurham and Seattle, US
Akira Matsuno(Executive Officer)Derek Jantz(Executive Officer)Charles Gersbach(Director)John McHutchison(CEO, Chairman of the Board)Dan McHugh(Executive Officer, Director)Blythe Sather(Executive Officer)
Co-investorsDuke Capital PartnersNew Enterprise Associates (NEA)Hatteras Venture PartnersYosemite
Terrestrial develops the Tacterra microarray patch platform, a dissolvable skin-patch technology for delivering therapies including GLP-1 without injection.
BiotechHealthtechMedical Devices
Rachel Sha(CEO)
Co-investorsNorwich VenturesUlu VenturesThe Engine Ventures
Vedere Bio develops optogenetics-based gene therapies for inherited retinal diseases (IRDs) and geographic atrophy (GA), using proprietary AAV vectors for intravitreal administration to restore vision in visually impaired patients globally.
BiotechDeep TechMedical DevicesCambridge, US
Co-investorsMission Bay Capital
Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types.
BiotechHealthtechMedical DevicesSan Mateo, US
Shuang Qiao(Executive Officer, Director)Sheng Ding(Executive Officer)
BoardEdward Hu(Director)Jun Wu(Director)Jake Simson(Director)inTim Shannon(Director)in
Co-investorsCanaan PartnersRA CapitalCenova Capital
Wildtype grows salmon directly from fish cells using cellular agriculture, allowing production of seafood without wild-caught or farmed fish.
BiotechClimate TechFoodTechSan Francisco, US
Justin Kolbeck(Executive Officer, Director)inArye Elfenbein(Director)
BoardJohn Melas-Kyriazi(Director)
Co-investorsBay Bridge Ventures ClimateCRV (Charles River Ventures)Maven VenturesRoot Ventures Manager, LlcS2G InvestmentsSpark Capital+2 more
BiotechBerkeley, US
Kelly Gardner(Executive Officer, Director)Elaine Heron(Director)Joshua Molho(Executive Officer, Director)
BoardDouglas Crawford(Director)
Engineers microbes that make useful molecules for everyday materials (acquired by Ginkgo Bioworks).
Emeryville, US
Erik (Jed) Dean(Executive Officer)Joshua Hoffman(Executive Officer, Director)Zachariah Serber(Executive Officer, Director)Josh Hoffman(Founder)inEnakshi Singh(Executive Officer)Aaron Kimball(Executive Officer)
Co-investorsAME Cloud VenturesCota CapitalDCVC (Data Collective)Hemisphere Ventures LLCKindred VenturesObvious Ventures+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 4
IPOs and acquisitions across the tracked portfolioAlectorNASDAQ: ALECCaribou BiosciencesNASDAQ: CRBUFluxionacq. by Cell MicrosystemsRedwood Bioscienceacq. by Catalent Pharma Solutions
Portfolio news
latest coverage across their companies
Sound · techcrunch.com · Aug 17, 2026
Zymergen · claimdepot.com · Jul 27, 2026
SiteOne Therapeutics · biopharmadive.com · Jul 20, 2026
Alector · dailypolitical.com · Jul 17, 2026
Jupiter Bioventures · trysignalbase.com · Jun 30, 2026
Frequently asked questions
- How many investments has Mission Biocapital made?
- Mission Biocapital has 59 tracked investments, 2 of which have exited via acquisition or IPO, including 4 dated in the last 24 months.
- What stage does Mission Biocapital invest at?
- Mission Biocapital invests at the Pre-Seed, Seed, Series A stages.
- What is Mission Biocapital's typical check size?
- Mission Biocapital typically writes checks of $500K.
- What sectors does Mission Biocapital focus on?
- Mission Biocapital focuses on Biotech, Deep Tech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Mission Biocapital located?
- Mission Biocapital is headquartered in San Francisco, US.
- Does Mission Biocapital lead rounds?
- Mission Biocapital typically participates in rounds rather than leading them.
- Who does Mission Biocapital co-invest with?
- Mission Biocapital most often shares deals with Mission Bay Capital, Berkeley Catalyst, Pfizer Venture Investments, among 137 tracked co-investors.
Images
Co-investors · 4
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
A healthcare-focused investment firm that partners with healthcare entrepreneurs to build novel technologies and therapeutics.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
Firms observed investing alongside Mission Biocapital, from public investor directories. Shared companies are the overlap with Mission Biocapital's recorded portfolio.
Similar investors
Future Positive Capital is a European deep-tech fund that ties its entire thesis to the Future Cones foresight framework, explicitly focusing on preferable futures and positioning itself as a futures-thinking, systems-change VC rather than a generic climate or impact fund. The firm hard-wires impact into its economics by contractually indexing more than 100% of partners' carried interest to portfolio companies achieving both financial and measurable impact outcomes, while specializing in capital-intensive, highly technical step-change solutions for planetary-scale problems like robotics for wind farm operations, large-scale carbon removal, and ecosystem restoration.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Snatched Ventures is a San Francisco-based early-stage venture capital firm backing DeepTech startups focused on sustainable innovation and operational transformation. It is led by a two-GP team combining corporate development and institutional investment management experience.
Crista Galli Ventures is a family office founded and run by physician scientists that invests in health and life-science innovation, backing exceptional founders and evidence-driven breakthroughs.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.